A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

A Site and Subject Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS 852927 in Patients With Primary Hypercholesterolemia on a Stable Dose of Statin Therapy

The purpose of this study is to evaluate the safety of BMS-852927 after 28 days of dosing in patients with high cholesterol.

Inclusion Criteria:

• Men and women, aged ≥18 to ≤75
• Body mass index (BMI) ≤ 40 kg/m2
• Primary hypercholesterolemia on a stable daily dose of a statin for ≥ 6 weeks
• Serum triglyceride levels at screening < 400mg/dL (< 4.52 mmol/L)

Exclusion Criteria:

• Any significant acute medical illness, significant cardiovascular history
• Current or history of hepatic or hepatobiliary disease
• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population